Gilead & Tibotec Expand HIV Drug Development Arrangement

Gilead will be responsible for the formulation, manufacturing, registration, distribution, and commercialization worldwide. Tibotec will have the right to co-detail the single-tablet regimen in certain major markets.

US-based biopharmaceutical company Gilead Sciences and Ireland-based Tibotec Pharmaceuticals have agreed to work together on the development and commercialization of a single-tablet regimen combining Tibotec’s Prezista? with Gilead’s Emtriva? and two investigational agents. These compounds include GS 7340, a novel prodrug of tenofovir, and cobicistat, a pharmacoenhancer.

Gilead will be responsible for the formulation, manufacturing, registration, distribution, and commercialization worldwide. Tibotec will have the right to co-detail the single-tablet regimen in certain major markets.

Subject to regulatory approval, Tibotec will be responsible for the formulation, manufacturing, registration, distribution, and commercialization of the fixed-dose combination of Prezista and cobic